Search

Various adverse effects particularly cutaneous manifestations associated with different COVID-19 vaccines have been observed in practice. The aim of our study was to evaluate all patients who presented to our tertiary center with skin manifestations following COVID-19 vaccines injection from September to December 2021. All patients with skin manifestation within 30 days or less following COVID-19 vaccination were enrolled in our case-series. All cases included in our study were diagnosed based on clinical and/or histopathological evaluation and all other possible differential diagnoses were ruled out. Twenty-five individuals including 16 (64%) males and 9 (36%) females with the mean age of 47 ± 17.62 years (range 18-91) were enrolled in our study. Twenty-two (88%) patients developed lesions after Sinopharm vaccine injection and 3 (12%) cases manifested lesions after the AstraZeneca vaccine. Six (24%) patients developed new-onset lichen planus (LP) and 1 (4%) patient manifested LP flare-up. Two (8%) individuals developed psoriasis and 1 (4%) case showed psoriasis exacerbation. One (4%) patient developed new-onset pemphigus vulgaris (PV) and 1 (4%) case experienced a flare of PV lesions. One (4%) patient manifested pityriasis lichenoides et varioliformis acuta (PLEVA) flare-up. Other new-onset cases were as follows: toxic epidermal necrolysis (TEN) (n = 1, 4%), bullous pemphigoid (BP) (n = 2, 8%), alopecia areata (AA) (n = 2, 8%), pytriasis rosea (n = 1, 4%), herpes zoster (n = 1, 4%), cutaneous small vessel vasculitis (n = 1, 4%), erythema multiform (EM) and urticaria (n = 3, 12%), and morphea (n = 1, 4%). Physicians should be aware of the possible side effects especially cutaneous manifestations associated with COVID-19 vaccines.

Geriatric psoriasis, due to its unusual clinical manifestations and higher rates of systemic complications in this age group, is a challenging issue for dermatologists. Therefore, we aimed to provide an overview of the epidemiological, clinical, and therapeutic consequences among patients aged over 60 years with psoriasis in a referral center in Iran. This cross-sectional study was conducted on 156 patients over 60 years with the definitive diagnosis of psoriasis that were referred to our center between 2015 and 2019. By reviewing the recorded files of the patients, baseline characteristics including demographics, underlying comorbidities, age of disease onset, clinical type of the disease, clinical manifestations, and therapeutic approaches were extracted. The most common clinical feature was plaque type (73.1%) followed by pustular type (10.9%). The most frequent involved zone was the lower extremities (84.6%). Most of the patients were treated topically (87.1%), while as the most frequent systemic approaches, methotrexate and acitretin were considered for 74.4% and 60.3%, respectively. A significantly higher mean age at disease onset was found in female patients compared to male patients. The plaque type was more prevalent in men than in women. Also, the chance of nail involvement was 2.43 times higher in men than in women (p = 0.011, 95%CI: 1.22-4.84). The disease duration was significantly longer in patients suffering from plaque compared to those without this feature. Conversely, those with palmoplantar type experienced shorter disease duration. Psoriatic arthritis was also revealed in patients of lower ages. As in other societies, in our society, clinical characteristics, disease involvement patterns, as well as considered treatment approaches, can be influenced by demographic characteristics.

Although the presence of morphea following COVID-19 has been rarely reported, development of its generalized form following COVID-19 vaccination has not been reported yet. Here, we reported the first case of generalized morphea following COVID-19 vaccination and another similar case following SARS-Cov-2 infection. Other etiologic factors were also dealt with

Background:Pemphigus is a rare autoimmune disease affecting the skin and mucosa. Metabolic dysfunctions are shown to be associated with this disorder. The pemphigus disease area index (PDAI) score has been used as an accurate tool to assess the severity of pemphigus. This study aimed to evaluate the association between nutritional, metabolic indexes and Phase angle (PhA) in patients with pemphigus vulgaris (PV) and severity of disease based on the PDAI index.Methods:In this regard, 103 pemphigus patients and 125 healthy cases who were matched regarding their sex, age and body mass index were chosen. Results:Our results showed that there was a significant correlation between phase angle and sarcopenic index in patients with PV. Moreover, steroid dose had a significant correlation with sarcopenia index; while had no correlation with visceral fat area (VFA), BMI, volume load, percent body fat (PBF), and PhA. The volume load was lower but phase angle and sarcopenic index were higher in males, and females had a significantly higher BMI. Moreover, PBF and VFA were significantly higher in females compared to males. Besides, patients treated with rituximab had lower PBF and higher sarcopenic index and volume loads compared to patients receiving other adjuvant treatments. In comparison to healthy controls, PV patients had a significantly higher VFA and PBF.Conclusion:Conclusively, patients with PV had a significantly higher VFA and PBF compared to healthy objects. Moreover, sarcopenic index was related to steroid dose and history of rituximab treatment.

here we report a case of cutaneous Pseudolymphoma progression to frank cutaneous lymphoma and resistant to conventional therapy after receiving Platelet-rich plasma and hair transplantation .these modalities and their proliferative formulation may be the leading cause or aggravating factor for such transformation’s specially for patients with positive family history